Navigation Links
Verenium Announces Debt Repurchase
Date:9/27/2011

SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company developing and commercializing high-performance enzymes, today announced that it retired its remaining secured 9% Notes through repurchase, leaving an aggregate of $34.9 million in principal amount of unsecured 5.5% Notes outstanding.

To effect this repurchase of approximately $1.1 million in principal amount of its 9% Notes, the Company paid a total of $1.2 million in cash to a single institutional investor, excluding accrued interest, as of the closing date.  

"We are pleased that we were able to retire the remainder of our 9% secured convertible Notes under favorable terms," said Jeffrey Black, Senior Vice President and Chief Financial Officer at Verenium.  "As stated previously, we will continue to address our remaining debt to further strengthen the capital structure and promote future growth."

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

Sarah CarmodyVice President, Corporate Communications

Manager, Corporate Communications858-431-8580

858-431-8581kelly.lindenboom@verenium.com

sarah.carmody@verenium.com
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
6. Verenium Announces First Commercial Cellulosic Ethanol Project
7. Verenium Announces Organizational Changes
8. Verenium Completes Amendment to 8% Senior Convertible Notes
9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
10. Verenium Announces Reverse Stock Split to Take Effect September 9
11. Verenium 1:12 Reverse Stock Split Takes Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... MERIDEN, Conn. , Jan. 12, 2017 /PRNewswire/ ... development company and maker of Flublok Influenza ... based Zika vaccine candidate had good safety results ... virus in preclinical studies. The product is expected ... next few months.  In addition, the Institute of ...
(Date:1/12/2017)... ... January 12, 2017 , ... In ... the platform to accommodate increasingly complex and sophisticated deployments, resulting in better ... In addition to these improvements, the latest release brings enhanced data import/export ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a graduate student, ... the pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages those diseases ... Now, as an assistant professor of biology and biotechnology at Worcester Polytechnic Institute ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... and costing healthcare systems more than $23.7 billion, healthcare systems are looking ... , Among the most common sepsis-causing pathogens are bacteria and the yeast pathogen ...
Breaking Biology Technology:
(Date:12/8/2016)... PUNE, India , Dec. 8, 2016 Market Research ... and Service Market. The global Mobile Biometric Security and Service Market ... period 2016 to 2022. Market Highlights: ... , , ... fast pace due to the increasing need of authentication and security ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... Avanade is helping Williams Martini Racing, one of ... biometric data in order to critically analyse every aspect ... against their rivals after their impressive, record-breaking pit stop ... with Williams during the 2016 season to capture and ... rate, temperature and peak acceleration) for key members of ...
Breaking Biology News(10 mins):